Denali Therapeutics (DNLI) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $17.61, -3.98% vs the prior close of $18.34.
- Volume 2.30M shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
DNLI slides 4.0% to $17.61, a 6-month low. Closed at $17.61, -3.98% vs the prior close of $18.34. Day range $17.37–$18.37, opened at $18.37.
DNLI daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — DNLI slides 4.0% to $17.61, a 6-month low
- Closed at $17.61, -3.98% vs the prior close of $18.34. Day range $17.37–$18.37, opened at $18.37.
- Volume was 2.30M shares, 1.4x its 50-day average of 1.61M.
- Price is -19.4% vs its 50-day average ($21.84) and -16.7% vs its 200-day average ($21.15).
- 52-week range $13.75–$27.30; today's close sits at 28% of that range, 35.5% below the 52-week high.
Oct 15, 2026 — DNLI rises 2.6% to $18.34
- Closed at $18.34, +2.63% vs the prior close of $17.87. Day range $18.00–$18.53, opened at $18.04.
- Volume was 1.57M shares, 1.0x its 50-day average of 1.60M.
- Price is -16.6% vs its 50-day average ($21.99) and -13.3% vs its 200-day average ($21.15).
- 52-week range $13.75–$27.30; today's close sits at 34% of that range, 32.8% below the 52-week high.
Oct 14, 2026 — DNLI dips 2.9% to $17.87, a 6-month low, 3 down days in a row
- Closed at $17.87, -2.88% vs the prior close of $18.40. Day range $17.53–$18.36, opened at $18.30.
- Volume was 2.70M shares, 1.7x its 50-day average of 1.56M.
- Price is -19.2% vs its 50-day average ($22.11) and -15.5% vs its 200-day average ($21.14).
- 52-week range $13.75–$27.30; today's close sits at 30% of that range, 34.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — DNLI dips 2.9% to $18.40, a 3-month low
- Closed at $18.40, -2.90% vs the prior close of $18.95. Day range $18.15–$19.19, opened at $18.82.
- Volume was 1.94M shares, 1.2x its 50-day average of 1.56M.
- Price is -17.2% vs its 50-day average ($22.23) and -12.9% vs its 200-day average ($21.13).
- 52-week range $13.75–$27.30; today's close sits at 34% of that range, 32.6% below the 52-week high.
Oct 12, 2026 — DNLI dips 2.6% to $18.95
- Closed at $18.95, -2.57% vs the prior close of $19.45. Day range $18.90–$19.62, opened at $19.33.
- Volume was 1.23M shares, 0.8x its 50-day average of 1.56M.
- Price is -15.1% vs its 50-day average ($22.33) and -10.3% vs its 200-day average ($21.12).
- 52-week range $13.75–$27.30; today's close sits at 38% of that range, 30.6% below the 52-week high.
Oct 9, 2026 — DNLI jumps 4.2% to $19.45
- Closed at $19.45, +4.18% vs the prior close of $18.67. Day range $18.46–$19.52, opened at $18.46.
- Volume was 1.34M shares, 0.9x its 50-day average of 1.55M.
- Price is -13.2% vs its 50-day average ($22.41) and -7.9% vs its 200-day average ($21.11).
- 52-week range $13.75–$27.30; today's close sits at 42% of that range, 28.8% below the 52-week high.
Oct 8, 2026 — DNLI dips 2.6% to $18.67, a 3-month low, 8 down days in a row
- Closed at $18.67, -2.56% vs the prior close of $19.16. Day range $18.30–$19.04, opened at $19.00.
- Volume was 2.37M shares, 1.5x its 50-day average of 1.53M.
- Price is -17.1% vs its 50-day average ($22.51) and -11.5% vs its 200-day average ($21.10).
- 52-week range $13.75–$27.30; today's close sits at 36% of that range, 31.6% below the 52-week high.
- That makes 8 straight losses.
Oct 7, 2026 — DNLI dips 0.6% to $19.16, a 3-month low, 7 down days in a row
- Closed at $19.16, -0.62% vs the prior close of $19.28. Day range $18.89–$19.43, opened at $18.95.
- Volume was 1.31M shares, 0.8x its 50-day average of 1.55M.
- Price is -15.3% vs its 50-day average ($22.61) and -9.2% vs its 200-day average ($21.09).
- 52-week range $13.75–$27.30; today's close sits at 40% of that range, 29.8% below the 52-week high.
- That makes 7 straight losses.
Oct 6, 2026 — DNLI slides 3.2% to $19.28, a 3-month low on 2.4x normal volume
- Closed at $19.28, -3.16% vs the prior close of $19.91. Day range $19.02–$19.97, opened at $19.93.
- Volume was 3.67M shares, 2.4x its 50-day average of 1.51M — unusually heavy trading.
- Price is -15.1% vs its 50-day average ($22.71) and -8.6% vs its 200-day average ($21.08).
- 52-week range $13.75–$27.30; today's close sits at 41% of that range, 29.4% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — DNLI dips 0.5% to $19.91, 5 down days in a row
- Closed at $19.91, -0.45% vs the prior close of $20.00. Day range $19.53–$20.09, opened at $20.09.
- Volume was 1.72M shares, 1.1x its 50-day average of 1.50M.
- Price is -12.7% vs its 50-day average ($22.80) and -5.5% vs its 200-day average ($21.07).
- 52-week range $13.75–$27.30; today's close sits at 45% of that range, 27.1% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — DNLI dips 2.6% to $20.00, 4 down days in a row
- Closed at $20.00, -2.58% vs the prior close of $20.53. Day range $19.93–$20.85, opened at $20.85.
- Volume was 1.63M shares, 1.1x its 50-day average of 1.49M.
- Price is -12.5% vs its 50-day average ($22.86) and -5.0% vs its 200-day average ($21.06).
- 52-week range $13.75–$27.30; today's close sits at 46% of that range, 26.7% below the 52-week high.
- That makes 4 straight losses.
DNLI latest news & SEC filings
Every SEC filing by or about DNLI in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Chin Peter Scott sold 1,654 shares at $22.29 (≈$36.87K) on Sep 4, 2026
- Chin Peter Scott sold 1,654 shares at $22.29 (≈$36.87K) on Sep 4, 2026
- Chin Peter Scott sold 1,654 shares at $22.29 (≈$36.87K) on Sep 4, 2026
- Chin Peter Scott sold 1,654 shares at $22.29 (≈$36.87K) on Sep 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Thornberry Nancy sold 10,824 shares at $22.85 (≈$247.33K) on Sep 2, 2026
- Thornberry Nancy sold 615 shares at $23.74 (≈$14.60K) on Sep 2, 2026
- Thornberry Nancy sold 10,824 shares at $22.85 (≈$247.33K) on Sep 2, 2026
- Thornberry Nancy sold 615 shares at $23.74 (≈$14.60K) on Sep 2, 2026
- Thornberry Nancy sold 10,824 shares at $22.85 (≈$247.33K) on Sep 2, 2026
- Thornberry Nancy sold 615 shares at $23.74 (≈$14.60K) on Sep 2, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Schuth Alexander O. sold 2,768 shares at $23.44 (≈$64.88K) on Sep 1, 2026
- Schuth Alexander O. sold 2,768 shares at $23.44 (≈$64.88K) on Sep 1, 2026
- Schuth Alexander O. sold 2,768 shares at $23.44 (≈$64.88K) on Sep 1, 2026
- Schuth Alexander O. sold 2,768 shares at $23.44 (≈$64.88K) on Sep 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $3.60M (prior year $0)
- Net income: -$127.55M (prior year -$124.12M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.68 (prior year -$0.72) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.01 — Completed an acquisition or sale of assets.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade DNLI
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.43% (largest 5.5%).
- Liquidity: about 2.01M shares (≈$35.31M) trade per day on average.
- 52-week position: $17.61 vs a range of $13.75–$27.30 (28% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Peter Scott Chin sold 1,654 shares on Sep 4, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jul 28, 2026.
- Share count: 159.85M shares outstanding (Jul 31, 2026), +9.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
DNLI market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 18.37 | 18.37 | 17.37 | 17.61 | 2.30M |
| Oct 15, 2026 | 18.04 | 18.53 | 18.00 | 18.34 | 1.57M |
| Oct 14, 2026 | 18.30 | 18.36 | 17.53 | 17.87 | 2.70M |
| Oct 13, 2026 | 18.82 | 19.19 | 18.15 | 18.40 | 1.94M |
| Oct 12, 2026 | 19.33 | 19.62 | 18.90 | 18.95 | 1.23M |
| Oct 9, 2026 | 18.46 | 19.52 | 18.46 | 19.45 | 1.34M |
| Oct 8, 2026 | 19.00 | 19.04 | 18.30 | 18.67 | 2.37M |
| Oct 7, 2026 | 18.95 | 19.43 | 18.89 | 19.16 | 1.31M |
| Oct 6, 2026 | 19.93 | 19.97 | 19.02 | 19.28 | 3.67M |
| Oct 5, 2026 | 20.09 | 20.09 | 19.53 | 19.91 | 1.72M |
| Oct 2, 2026 | 20.85 | 20.85 | 19.93 | 20.00 | 1.63M |
| Oct 1, 2026 | 20.55 | 20.85 | 20.40 | 20.53 | 1.94M |
| Sep 30, 2026 | 20.95 | 21.08 | 20.51 | 20.67 | 2.26M |
| Sep 29, 2026 | 20.88 | 21.01 | 20.41 | 20.81 | 1.39M |
| Sep 28, 2026 | 20.05 | 21.26 | 19.93 | 20.98 | 2.56M |
| Sep 25, 2026 | 20.46 | 20.59 | 19.96 | 20.39 | 1.26M |
| Sep 24, 2026 | 20.40 | 20.64 | 19.73 | 20.47 | 2.27M |
| Sep 23, 2026 | 21.50 | 21.51 | 20.33 | 20.46 | 1.91M |
| Sep 22, 2026 | 20.75 | 21.79 | 20.47 | 21.60 | 2.34M |
| Sep 21, 2026 | 19.99 | 20.55 | 19.40 | 20.47 | 2.39M |
About Denali Therapeutics
Denali Therapeutics (DNLI) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SOUTH SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1714899.
DNLI board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| L.P. 667, | Director | Jun 5, 2026 |
| Bros. Advisors Lp Baker | Director | Jun 5, 2026 |
| Felix Baker | Director | Jun 5, 2026 |
| Julian Baker | Director | Jun 5, 2026 |
| Bros. Advisors (Gp) Llc Baker | Director | Jun 5, 2026 |
| Brothers Life Sciences Lp Baker | Director | Jun 5, 2026 |
| Jennifer E. Cook | Director | Jun 5, 2026 |
| Jay T Flatley | Director | Jun 5, 2026 |
| Peter S Klein | Director | Jun 5, 2026 |
| Steve E. Krognes | Director | Jun 5, 2026 |
| David P Schenkein | Director | Jun 5, 2026 |
| Nancy Thornberry | Director | Sep 4, 2026 |
| Hauwermeiren Timothy Van | Director | Jun 5, 2026 |
| Ryan J. Watts | President and CEO | Aug 14, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Peter Scott Chin | Chief Medical Officer | Sep 9, 2026 |
| Alexander O. Schuth | COFO and Secretary | Sep 3, 2026 |
| Ryan J. Watts | President and CEO | Aug 14, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 4, 2026 | Peter Scott Chin | Sale | 1,654 | $22.29 |
| Sep 4, 2026 | Peter Scott Chin | Sale | 1,654 | $22.29 |
| Sep 4, 2026 | Peter Scott Chin | Sale | 1,654 | $22.29 |
| Sep 4, 2026 | Peter Scott Chin | Sale | 1,654 | $22.29 |
| Sep 2, 2026 | Nancy Thornberry | Sale | 10,824 | $22.85 |
| Sep 2, 2026 | Nancy Thornberry | Sale | 615 | $23.74 |
| Sep 2, 2026 | Nancy Thornberry | Sale | 10,824 | $22.85 |
| Sep 2, 2026 | Nancy Thornberry | Sale | 615 | $23.74 |
| Sep 2, 2026 | Nancy Thornberry | Sale | 10,824 | $22.85 |
| Sep 2, 2026 | Nancy Thornberry | Sale | 615 | $23.74 |
| Sep 2, 2026 | Nancy Thornberry | Sale | 10,824 | $22.85 |
| Sep 2, 2026 | Nancy Thornberry | Sale | 615 | $23.74 |
| Sep 1, 2026 | Alexander O. Schuth | Sale | 2,768 | $23.44 |
| Sep 1, 2026 | Alexander O. Schuth | Sale | 2,768 | $23.44 |
| Sep 1, 2026 | Alexander O. Schuth | Sale | 2,768 | $23.44 |
DNLI financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-512.54M | -2.97 | $-412.60M |
| Dec 31, 2024 | $0 | $-422.77M | -2.57 | $-347.69M |
| Dec 31, 2023 | $330.53M | $-145.22M | -1.06 | $-357.99M |
| Dec 31, 2022 | $105.06M | $-325.99M | -2.60 | $-244.72M |
| Dec 31, 2021 | $48.66M | $-290.58M | -2.39 | $-211.39M |
Latest balance sheet: total assets $1.16B, total liabilities $322.78M, cash $201.53M (as of Jun 30, 2026).
DNLI earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $24.73 |
| May 7, 2026 | 8-K Item 2.02 (results) | $19.71 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $21.42 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $14.41 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $13.92 |
| May 6, 2025 | 8-K Item 2.02 (results) | $13.97 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $18.60 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $29.55 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on DNLI
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.